Ocugen OCGN
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Ocugen (OCGN) Business Model and Operations Summary
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Key Insights
Ocugen (OCGN) Core Market Data and Business Metrics
Latest Closing Price
$0.689Market Cap
$190.48 MillionAverage Daily Trade Volume
4,142,776 SharesTotal Outstanding Shares
292.01 Million SharesCEO
Dr. Shankar Musunuri M.B.A., Ph.D.Total Employees
95Dividend
No dividendIPO Date
December 3, 2014SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
11 Great Valley Parkway, Malvern, PA, 19355
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Short Interest
This information is bi-monthly aggregated short interest data reported to the Financial Industry Regulatory Authority (FINRA) by broker-dealers.
Average Daily Volume: The average number of shares traded per day over the specified period.
Days to Cover: The estimated number of days it would take to cover all short positions based on average trading volume.
Settlement Date: The date on which the short interest data is considered settled, typically based on exchange reporting schedules.
Short Interest: The total number of shares that have been sold short but have not yet been covered or closed out.
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Short Interest | Bi-Weekly Change (%) | Settlement Date | Days to Cover |
|---|---|---|---|
| 67,513,578 Shares | +6.03% | 3/14/2025 | 16.38 |
| 63,673,877 Shares | +5.67% | 2/28/2025 | 17.89 |
| 60,259,171 Shares | +2.34% | 2/14/2025 | 17.46 |
| 58,883,625 Shares | +4.94% | 1/31/2025 | 15.35 |
| 56,110,366 Shares | +7.37% | 1/15/2025 | 10.16 |
| 52,258,018 Shares | -10.87% | 12/31/2024 | 7.56 |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities | $-42.14 Million |
| Net Cash Flow From Investing Activities, Continuing | $-3.38 Million |
| Exchange Gains/Losses | $28,000 |
| Net Cash Flow From Investing Activities | $-3.38 Million |
| Net Cash Flow From Operating Activities, Continuing | $-42.14 Million |
| Net Cash Flow From Financing Activities | $64.86 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Benefits Costs and Expenses | $58.11 Million |
| Costs And Expenses | $58.11 Million |
| Income/Loss From Continuing Operations Before Tax | $-54.05 Million |
| Operating Expenses | $58.81 Million |
| Operating Income/Loss | $-54.76 Million |
| Net Income/Loss Attributable To Parent | $-54.05 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $28,000 |
| Comprehensive Income/Loss | $-54.03 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $-54.03 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Assets | $82.44 Million |
| Accounts Payable | $4.24 Million |
| Liabilities | $52.81 Million |
| Liabilities And Equity | $82.44 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
| Noncurrent Assets | $20.76 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||